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Cost-containment in healthcare spending has become a central issue in public policy and healthcare reform, especially
as the affordable care act adds millions of people to public and private insurance rolls. In this climate, longstanding
criticism of pharmaceutical pricing has grown sharper, and many in both policy and medicine have characterized the
costs of newly developed drugs as both exorbitant and wasteful of scarce healthcare resources. At the same time,
pharmaceutical research and development pipeline costs are increasing exponentially.
Price resistance poses a significant threat to the development of drugs to treat rare pediatric diseases, where
exceptionally high prices are a sine qua non of commercial viability. This article examines the trends in public
discussion of high cost drugs and the potential consequences for orphan drug development. We conclude that
despite growing public hostility towards high unit costs, drugs that treat rare diseases in children are likely to
remain well-compensated and commercially viable.
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Although total sales of pharmaceuticals in the United
States were essentially flat from 2007 to 2012, this stable
revenue conceals a marked shift in the industry, as drug
companies have increasingly benefited from aggressive
pricing despite declining volumes of drugs sold [1].
(Figure 1) This trend has many plausible causes, from
routine changes in portfolio composition due to patent
expirations of particularly successful mass market drugs,
to evolving healthcare delivery and payment systems, and
even fundamental improvements in basic science and
biotechnology. But whatever the cause, this trend has
significant political and public health implications, and
therefore is of serious concern to those who discover,
develop, manufacture, or recommend the use of very
high cost drugs.Discussion
Drugs that cost hundreds of thousands of dollars per
year make for sensational bullet points in debates over
healthcare cost containment. Whereas other major cost
drivers, such as dialysis or joint replacements, bring to* Correspondence: Peter.Stella@nyumc.org
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this article, unless otherwise stated.mind images of ill people undergoing dangerous and
complex therapies with the help of skilled professionals,
it is much harder to justify the idea of a single pill, which
needs only be swallowed, costing as much a person may
make in a month. Put another way, expensive drugs are
easy to criticize because the efforts expended to develop
them are extremely costly, but these costs are hard for
the casual observer to see. Additionally, for most well
people who do not spend much of their time in the hos-
pital or at doctors’ offices, pharmaceuticals are the most
visible part of the healthcare system with which they
interact commercially or financially.
In any case, the point remains that expensive drugs at-
tract disproportionate attention and hostility in political
and policy discussions. The negative press that this gen-
erates is particularly worrisome in the case of rare dis-
eases that affect children, where high drug pricing,
broad political support, and favorable regulatory atti-
tudes have long been the bedrock of the economic “deal”
between industry, government, and researchers under-
lying the development of therapies for previously un-
treatable “orphan” diseases. The prices for these drugs
are, and always have been, very high.
The first drug approved for enzyme replacement ther-
apy for a lysosomal storage disease, Genzyme’s CeredaseBioMed Central Ltd. This is an Open Access article distributed under the terms of
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Figure 1 Recent drug approvals, volumes, and prices. (a. Trajectory of FDA Approval for Orphan Drugs, 1984-2012 [11]. b. Recent trends in
pharmaceutical revenue, pricing and volume) [1].
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mately $150,000 per year (in 1991 dollars). Prices of
these magnitude are far from unusual in the fields of
metabolic disease and genetics. Ceredase’s successor,
Cerezyme currently costs approximately $200,000 for
every year of therapy. Other drugs, in areas like pulmonol-
ogy or immunology, can be even more expensive, as Vertex
pharmaceuticals new CF treatment Ivacaftor (kalydeco)
launched with a price of over $300,000 per year.
Despite a long history as the status quo, and a share of
total healthcare spending that is estimated at only ~ 0.5%
[2], the combination of public focus on cost containment
and dramatic prices has begun to make even those dir-
ectly responsible for the care of children with rare ill-
nesses fear that expenditures on pharmaceuticals for
rare disease will consume resources that could provide
more patient benefit elsewhere [3-5].
However, despite these fears, regulatory commitment
to high prices for orphan drugs remains strong, as can
be seen in the recent debate over the United States
Department of Health and Human Services’ (HHS) at-
tempt to apply 340b pricing to orphan drugs under some
circumstances. Although this attempt has been invali-
dated in a recent court case on the grounds that it repre-
sented an illegal extension of regulatory discretion into
the legislative sphere, the specifics of HHS’s original in-
tentions are illuminating when it comes to evaluating
the prospects of very high priced drugs [6].
These drugs have relied favorable regulatory and legis-
lative treatment that began with the Orphan Drug Act of1983 (ODA), which was specifically designed to create
the financial incentives for pharmaceutical companies to
develop treatments for drugs outside of the traditional
mass market, small molecule paradigm. It provides sev-
eral incentives including a seven year market exclusivity
window independent of patent protection, waiver of
FDA fees, and tax breaks for drugs to treat conditions
defined as rare, that is with a prevalence of under
200,000 people in the United States.
In contrast to this system of generous supports, the
340b program is an example of stern government price
control. It requires drug companies to offer discounted
drugs to “safety net” organizations, including HIV centers,
hospitals with Medicaid heavy payor mixes, children’s
hospitals, and others [7], although the laws governing the
program explicitly excluded orphan drugs. The Affordable
Care Act (ACA) mandated the expansion of this program
to several new types of organization, and in July 2013,
HHS released a ruling stating that 340b discounts should
be applied to orphan drugs, when those drugs were used
for conditions other than those for which they received
orphan designations [8].
Although the idea of pushing industry to lower prices
on orphan drugs might seem to indicate an erosion of
support for the project of orphan drug development, the
focus on indications is revealing of HHS’s likely goals.
This is because while the “idea” of an orphan drug is a
specific therapy directed a single rare disease, orphan
status is given to a far wider range of agents, including
those that are are used outside that designation for a
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mon. This is particularly true in oncology where, many
anti-neoplastics, such as Imatinib mesylate, (Gleevec®,
Novartis Oncology), actually have multiple orphan designa-
tions. Overall, there are 1.5 orphan designations per ap-
proved drug, and as much as 90% of sales for drugs with
orphan designations come outside of that orphan window
[9]. Furthermore, many drugs have orphan designation
only by virtue of relative narrow indications, such as for
use as second or third line treatments, or in highly specific
populations [10].
Taken in this context, HHS attempt to apply 340b pri-
cing appears to be a very specific cost control measure,
aimed at combatting the expanding use of the ODA by
the pharmaceutical industry and to erode the status of
drugs whose orphan status is based on a narrow indica-
tion or use in a subset of a more common disease.
In fact, what is remarkable here is that congress pro-
vided explicit protection of orphan drugs from drug dis-
counting, and HHS, though clearly under pressure to
undermine drug prices, showed no desire to place pres-
sure on orphan indications, which in our reading signals
an unusually solid commitment on the part of the regu-
latory and legislative community to protect the eco-
nomic value of treatments for rare diseases, even in the
face of mounting pressures on healthcare spending.
In the short term, there is no doubt that the Court’s
ruling adds value to having an orphan designation in
that it protects a drug from 340b discounting. As a con-
sequence, we may expect an attempt by pharmaceutical
companies to have their high priced “specialty” drugs so
designated by financing new studies in orphan areas.
However it is possible that HHS will appeal this ruling,
or that the court’s decision could spur legislative action
to ratify HHS’s interpretation of the rule. It is reasonable
to ask what effects that a successful appeal or new legis-
lation might have on the market for further orphan drug
development. But even in such a case we see no indica-
tion in the treatment of this case that suggests any desire
to create price pressure on drugs used for “real” orphan
designations.
So while regulatory and legislative bodies are likely to
continue to support incentives for drugs developed to
treat “truly” rare disease, another threat looms- the will-
ingness and ability of payors to continue to provide re-
imbursement at the very high (> $100,000/year) costs
that is required to make these drugs economically viable
for their developers. Assuming that payors behave as
profit maximizing entities, their current high willingness
to pay is driven by a simple calculation. While orphan
drugs are strikingly expensive on a unit basis, the total
volume of drug sold is so low that the impact on payors
is minor, especially considering the reputational risk in-
volved in denying disease-modifying treatment to pediatricpatients. However, there is a perception among some that
the number of these expensive drugs is increasing, and that
the total cost of such drugs will continue to mount [11].
This perception, however, is more fear than fact. While
it is true that there has been an increase in the number
of drugs applying for orphan designations, drug ap-
provals for these drugs have been essential flat since
2006. The overall number of annual FDA approvals
for orphan drugs has not increased since 1996 [11].
(Figure 1b). When this is taken in concert with the
previously mentioned issue of “narrow indication” or-
phan status, and the fact that very few of these orphan
drugs are actually being used in children, the notion of
an exploding number of treatments for rare pediatric dis-
ease is unfounded.
Other recent legislative changes should provide add-
itional support for the development of therapies for rare
pediatric diseases, such as the pediatric rare disease vou-
cher program, which has provided vouchers offering pri-
ority review for an additional drug to firms who develop
orphan drugs for orphan drugs which occur in those
under 18 years of age. There are also provisions in the
ACA or an accelerated approval program for “break-
through drugs” that could be applied to most therapies
for these diseases. Finally, the ACA mandates an in-
creased role for patient stakeholders in FDA reviews,
and in doing so, will place significant pressure on FDA
to look favorably on these drugs, as rare disease and
disease-specific patient advocacy working groups are
quite savvy at leveraging power and forging pharmaceut-
ical partnerships.
Summary
Taken together, the variety of incentives created to en-
courage the development of new therapies rare pediatric
diseases, and regulatory willingness to exclude these ther-
apies even while attempting to impose cost containment
on orphan designated drugs overall paints a reassuring pic-
ture for those who are concerned that unit price sensitivity
will threaten the development of these therapies.
Cost pressures are undoubtedly a serious risk for the
drug discovery and development industry, but the drugs
used to treat rare pediatric diseases will likely remain a
special, protected class, well insulated from the general
climate. As such, pediatric rare and orphan drug devel-
opment should continue to be an island of opportunity
for industry, and a source of hope and solace for patients,
families, and the community.
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